Global Information
회사소개 | 문의 | 비교리스트

VRAYLAR : 신약 인사이트와 시장 예측(2032년)

VRAYLAR Emerging Drug Insight and Market Forecast - 2032

리서치사 DelveInsight Business Research LLP
발행일 2022년 09월 상품코드 1125993
페이지 정보 영문 30 Pages 배송안내 1-2일 (영업일 기준)
가격
US $ 3,250 ₩ 4,698,000 PDF (Single User License)
US $ 6,500 ₩ 9,397,000 PDF (Site License)
US $ 9,750 ₩ 14,096,000 PDF (Global License)


VRAYLAR : 신약 인사이트와 시장 예측(2032년) VRAYLAR Emerging Drug Insight and Market Forecast - 2032
발행일 : 2022년 09월 페이지 정보 : 영문 30 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

치료 저항성 우울증 치료제의 일종인 VRAYLAR 시장 구조·동향에 대해 분석했으며, 제품 개요(용법·용량, 작용기서 등)과 관련 규제, 제품 개발·임상시험 진행 상황, 주요 7개국(미국, 유럽 5개국(독일, 프랑스, 이탈리아, 스페인, 영국), 일본) 시장 규모 동향 전망(2023-2032년), 시장 경쟁 상황·SWOT 분석, 기타 치료제와의 경쟁 상황, 향후 시장 성장 가능성 등을 조사·제시하고 있습니다.

목차

제1장 분석 개요

제2장 치료 저항성 우울증용 VRAYLAR : 개요

  • 제품 상세
  • 임상 개발
    • 임상 연구
    • 임상시험 정보
    • 안전성과 유효성
  • 기타 개발 활동
  • 제품 프로파일

제3장 경쟁 상황(후기 단계 신흥 치료제)

제4장 VRAYLAR 시장 평가

  • 치료 저항성 우울증용 VRAYLAR : 시장 전망
  • 주요 7개국의 시장 분석
    • 치료 저항성 우울증용 VRAYLAR : 주요 7개국의 시장 규모
  • 국가별 시장 분석
    • 미국
    • 독일
    • 영국

제5장 SWOT 분석

제6장 애널리스트의 견해

제7장 부록

제8장 DelveInsight 서비스 내용

제9장 면책사항

제10장 DelveInsight 소개

제11장 보고서 구입 옵션

KSM 22.09.23

List of Tables

  • Table 1: VRAYLAR, Clinical Trial Description, 2022
  • Table 2: VRAYLAR, General Description, 2022
  • Table 3: Competitive Landscape (Emerging Therapies)
  • Table 4: VRAYLAR Market Size in the 7MM, in USD million (2019-2032)
  • Table 5: VRAYLAR Market Size in the US, in USD million (2019-2032)
  • Table 6: VRAYLAR Market Size in Germany, in USD million (2019-2032)
  • Table 7: VRAYLAR Market Size in France, in USD million (2019-2032)
  • Table 8: VRAYLAR Market Size in Italy, in USD million (2019-2032)
  • Table 9: VRAYLAR Market Size in Spain, in USD million (2019-2032)
  • Table 10: VRAYLAR Market Size in the UK, in USD million (2019-2032)
  • Table 11: VRAYLAR Market Size in Japan, in USD million (2019-2032)

List of Figures

  • Figure 1: VRAYLAR Market Size in the 7MM, USD million (2019-2032)
  • Figure 2: VRAYLAR Market Size in the United States, USD million (2019-2032)
  • Figure 3: VRAYLAR Market Size in Germany, USD million (2019-2032)
  • Figure 4: VRAYLAR Market Size in France, USD million (2019-2032)
  • Figure 5: VRAYLAR Market Size in Italy, USD million (2019-2032)
  • Figure 6: VRAYLAR Market Size in Spain, USD million (2019-2032)
  • Figure 7: VRAYLAR Market Size in the United Kingdom, USD million (2019-2032)
  • Figure 8: VRAYLAR Market Size in Japan, USD million (2019-2032)

"VRAYLAR, Emerging Drug Insight and Market Forecast - 2032" report provides comprehensive insights about VRAYLAR for Treatment Resistant Depression in seven major markets. A detailed picture of the VRAYLAR for Treatment Resistant Depression in 7MM, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan, for the study period 2019 -2032 is provided in this report along with a detailed description of the VRAYLAR for Treatment Resistant Depression. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the VRAYLAR market forecast analysis for Treatment Resistant Depression in 7MM, SWOT, analyst views, comprehensive overview of market competitors, and brief about other emerging therapies in Treatment Resistant Depression.

Drug Summary:

VRAYLAR also known as Cariprazine is an oral, once-daily atypical antipsychotic. It is a potent central dopamine D3 and D2 receptor partial agonist, which preferentially binds to the D3 receptor. It also has partial agonist activity at serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Pharmacodynamic studies with cariprazine have shown that it acts as a partial agonist with a high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors. Cariprazine demonstrated up to eightfold greater in vitro affinity for dopamine D3 vs. D2 receptors. Cariprazine also acts as an antagonist at serotonin 5-HT2B and 5-HT2A receptors with high and moderate binding affinity, respectively, as well as it binds to the histamine H1 receptors. It shows a lower binding affinity to the serotonin 5-HT2C and α1A-adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors.

It was discovered and co-developed by Gedeon Richter and is licensed to Actavis, now Allergan, in the US and Canada. For more than a decade, both companies have conducted over 20 clinical trials enrolling thousands of patients worldwide to evaluate the efficacy and safety of cariprazine for patients suffering from a broad range of mental health illnesses.

Scope of the Report:

The report provides insights into:

  • A comprehensive product overview including the VRAYLAR description, mechanism of action, dosage and administration, research and development activities in Treatment Resistant Depression.
  • Elaborated details on VRAYLAR regulatory milestones and other development activities have been provided in this report.
  • The report also highlights the VRAYLAR research and development activities in Treatment Resistant Depression across the United States, Europe and Japan.
  • The report also covers the patents information with expiry timeline around VRAYLAR.
  • The report contains forecasted sales of VRAYLAR for Treatment Resistant Depression till 2032.
  • Comprehensive coverage of the late-stage emerging therapies for Treatment Resistant Depression.
  • The report also features the SWOT analysis with analyst views for VRAYLAR in Treatment Resistant Depression.

Methodology:

The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

VRAYLAR Analytical Perspective by DelveInsight

  • In-depth VRAYLAR Market Assessment

This report provides a detailed market assessment of VRAYLAR for Treatment Resistant Depression in seven major markets, i.e., United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. This segment of the report provides forecasted sales data from 2023 to 2032.

  • VRAYLAR Clinical Assessment

The report provides the clinical trials information of VRAYLAR for Treatment Resistant Depression covering trial interventions, trial conditions, trial status, start and completion dates.

Report Highlights:

  • In the coming years, the market scenario for Treatment Resistant Depression is set to change due to the extensive research and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market.
  • The companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence VRAYLAR dominance.
  • Other emerging products for Treatment Resistant Depression are expected to give tough market competition to VRAYLAR and launch of late-stage emerging therapies in the near future will significantly impact the market.
  • A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of VRAYLAR in Treatment Resistant Depression.
  • Our in-depth analysis of the forecasted sales data of VRAYLAR from 2023 to 2032 will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the VRAYLAR in Treatment Resistant Depression.

Key Questions

  • What is the product type, route of administration and mechanism of action of VRAYLAR?
  • What is the clinical trial status of the study related to VRAYLAR in Treatment Resistant Depression and study completion date?
  • What are the key collaborations, mergers and acquisitions, licensing and other activities related to the VRAYLAR development?
  • What are the key designations that have been granted to VRAYLAR for Treatment Resistant Depression?
  • What is the forecasted market scenario of VRAYLAR for Treatment Resistant Depression?
  • What are the forecasted sales of VRAYLAR in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain, and the United Kingdom), and Japan?
  • What are the other emerging products available and how are these giving competition to VRAYLAR for Treatment Resistant Depression?
  • Which are the late-stage emerging therapies under development for the treatment of Treatment Resistant Depression?

Table of Contents

1. Report Introduction

2. VRAYLAR overview in Treatment Resistant Depression

  • 2.1. Product Detail
  • 2.2. Clinical Development
    • 2.2.1. Clinical Studies
    • 2.2.2. Clinical Trials Information
    • 2.2.3. Safety and Efficacy
  • 2.3. Other Developmental Activities
  • 2.4. Product Profile

3. Competitive Landscape (Late-stage Emerging Therapies)

4. VRAYLAR Market Assessment

  • 4.1. Market Outlook of VRAYLAR in Treatment Resistant Depression
  • 4.2. 7MM Market Analysis
    • 4.2.1. Market Size of VRAYLAR in the 7MM for Treatment Resistant Depression
  • 4.3. Country-wise Market Analysis
    • 4.3.1. Market Size of VRAYLAR in the United States for Treatment Resistant Depression
    • 4.3.2. Market Size of VRAYLAR in Germany for Treatment Resistant Depression
    • 4.3.3. Market Size of VRAYLAR in France for Treatment Resistant Depression
    • 4.3.4. Market Size of VRAYLAR in Italy for Treatment Resistant Depression
    • 4.3.5. Market Size of VRAYLAR in Spain for Treatment Resistant Depression
    • 4.3.6. Market Size of VRAYLAR in the United Kingdom for Treatment Resistant Depression
    • 4.3.7. Market Size of VRAYLAR in Japan for Treatment Resistant Depression

5. SWOT Analysis

6. Analysts' Views

7. Appendix

  • 7.1. Bibliography
  • 7.2. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

11. Report Purchase Options

Back to Top
전화 문의
F A Q